Hatteras Venture Partners — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)Nadim Yared(Executive Officer, Director)Dean Bruhn-Ding(Executive Officer)John Brintnall(Executive Officer)Liz Galle(Executive Officer)
BoardGeoff Pardo(Director)
Co-investorsNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalVensana Capital
BiotechBrisbane, US
John S. Patton, Ph.D(Executive Officer, Director)Tyler Martin, M.D.(Executive Officer, Director)Greg Zante(Executive Officer)Lisa E. Porter, M.D.(Executive Officer)
BoardAdam Stern(Director)Augustine P.Y. Chow, M.D.(Director)
Board seatKenneth B. Lee, Jr.· per SEC Form D · $15M raise · filed Jun 2020
HealthtechNew York, US
Kate Hershov(Director)Kim Chilman-Blair(Executive Officer, Director)Mitzie Garland(Executive Officer)
BoardFredric Eshelman(Director)Jonathan Comerford(Director)
Board seatJohn Crumpler· per SEC Form D · $2.3M raise · filed Aug 2020
BiotechBoston, US
Robin Y. Smith(Executive Officer, Director, Promoter)Kate Blanchard(Executive Officer, Director, Promoter)
BoardDoug Jamison(Director)Jonathan Meltzer(Director)
Board seatClay Thorp· per SEC Form D · $28.7M raise · filed Sep 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.